News

Clinical development of the oral chemotherapy agent, tesetaxel is being discontinued as the treatment of metastatic breast cancer, colorectal cancer, and other solid tumors after the FDA provided feedback on a pre-New Drug Application.

177Lu-PSMA-617, a targeted radioligand therapy, demonstrated improvement in both progression-free survival and overall survival as treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer compared with best standard of care alone in the phase 3 VISION trial.

Heinz-Josef Lenz, MD, discusses immunogenic cell death and the results of using irinotecan versus oxaliplatin in an interview with Targeted Oncology.

An update from the phase 3 IMpower010 study shows that the study has met its primary end point of improvement in disease-free survival with atezolizumab versus use of best supportive care as treatment of patients with non–small cell lung cancer.

Melphalan flufenamide has been added to the Multiple Myeloma Clinical Practice Guidelines of the National Comprehensive Cancer Network, for the treatment of adult patients with relapsed or refractory multiple myeloma who have had at least 4 prior lines of therapy.

Tanya B. Dorff, MD, a medical oncologist at the City of Hope Cancer Center, discusses the reasoning behind using PSCA-targeted chimeric antigen receptor T-cell therapy and the design of this early study in an interview with Targeted Oncology.

The FDA has approved pembrolizumab in combination with platinum and fluoropyrimidine-based chemotherapy for the treatment of patients with metastatic or locally advanced esophageal or gastroesophageal junction carcinoma who are not eligible for surgical resection or definitive chemoradiation.

Bexmarilimab, a novel anti-Clever-1 antibody, has shown signals of significant efficacy as a treatment of patients with 10 hard-to-treat solid tumors, according to an update from the phase 1/2 MATINS clinical trial.

The modified Appleby procedure, a technique that removes two-thirds of the pancreas, the spleen, and the celiac axis, offers patients with pancreatic cancer another treatment option.

Eric Pujade-Lauraine, MD, PhD, discussed PARP inhibitors and the benefits of various testing methods for HRD, in an interview with Targeted Oncology ahead of the Society of Gynecologic Oncology Annual Meeting on Women's Cancer.

Ursula A. Matulonis, MD, discusses the effect of the PARP inhibitor niraparib on recurrent ovarian cancer.

After long-term follow-up, olaparib maintenance therapy demonstrated progression-free survival benefit in almost half of the patients with ovarian cancer compared with 21% for those who received placebo, including consistent benefit in high- and low-risk patients.

At the Society of Gynecological Oncology Virtual Annual Meeting on Women’s Cancer data from the phase II OVARIO study continued to show the progression free survival benefit for heavily pretreated patients with advanced ovarian cancer.

Shannon Westin, MD, MPH, FACOG, discusses the rationale of using durvalumab, a PD-L1 inhibitor, with or without olaparib.

Progression-free survival and overall survival were improved with pembrolizumab and lenvatinib when compared with chemotherapy in patients with advanced endometrial cancer who had received prior platinum-based chemotherapy in the phase 3 Study-309/KEYNOTE-775 trial.

The addition of the investigational anti–PD-1 immunotherapy agent, dostarlimab, to niraparib and bevacizumab demonstrated positive antitumor activity and tolerability in patients with platinum-resistant ovarian cancer.

The combination of tilsotolimod and ipilimumab demonstrated a low objective response rate in patients with anti–PD-1–refractory advanced melanoma, missing the coprimary end point of the phase 3 ILLUMINATE-301 trial.

Andre Goy, MD, MS, discusses the results of the ZUMA-2 study of the chimeric antigen receptor T-cell therapy

Most of the time, evidence of a cancer therapy’s success in clinical trials is reassuring. This time, it was not.

Major thrombosis is a significant danger for patients with MPN who become infected with COVID-19, and antithrombotic prophylaxis does not appear to eliminate the risk.

Although chemotheray remains a standard in the first- and second-line setting of biliary tract cancer in the locally advanced and metastatic setting, further treatments are emerging rapidly.

The FDA has approved TheraSphere yttrium-90 glass microspheres for the treatment of patients with unresectable hepatocellular carcinoma.

The FDA has granted CYNK-001, a natural killer cell therapy, with a fast track designation for the treatment of adult patients with recurrent glioblastoma multiforme, according to a press release from developer Celularity.

Sotorasib demonstrated significant benefit in patients with KRAS G12C–mutated advanced non–small cell lung cancer who progressed after standard treatment, according to results from the phase 2 portion of the CodeBreaK 100 trial .

Bintrafusp alfa monotherapy demonstrated efficacy, durability, and a manageable safety profile in patients with locally advanced or metastatic biliary tract cancer who have progressed or are intolerant to first-line platinum-based chemotherapy in a phase 2 study, but failed to meet the pre-determined threshold for a regulatory filing.

The Center for Cancer and Blood Disorders, which serves 12,000 patients a year in North Texas, is now offering their patients and caregivers the COVID-19 vaccine.

The FDA has granted an orphan drug designation to ARX788 for the treatment of patients with HER2-positive gastric cancer, according to a press release from developer Ambrx.

Despite the coronavirus disease 2019 pandemic, major progress in cancer research has been made in the past year in the areas of molecular profiling, biomarker-driven treatment approaches, targeted therapies brought into earlier stages of disease, treatment combinations with limited toxicities, and treatments that extend survival for hard-to-treat cancers.